Key facts
- Eugene Labs’s last known valuation is $7.0M (Dec 2021).
- It has raised $5.2M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Flying Fox Ventures, ANDHealth, Avalanche Technology Group, ALIAVIA Ventures, Adam Milgrom — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Eugene Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Eugene Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eugene Labs
Operator of a digital healthcare company intended to offer genetic plus health services. The company's platform offers at-home genetic tests, in-app counseling, carrier testing, and proactive cancer risk assessments, enabling clients to access expert, convenient, and compassionate healthcare.
- Sector
- Healthcare
- HQ
- Richmond, Australia
- Founded
- 2017
- Employees
- 63
- Website
- eugenelabs.com/
- Ownership
- Privately Held (backing)
Eugene Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eugene Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eugene Labs in its N-PORT filings yet. We sweep new filings monthly.